IPCA Laboratories climbed 6.24% to Rs 1073.40 after consolidated net profit surged 63% to Rs 193.54 crore on 26.86% rise in net sales to Rs 1,283.90 crore in Q2 September 2019 over Q2 September 2018.
Consolidated EBITDA before forex (gain)/loss rose 29% to Rs 282.99 crore in Q2 September 2019 over Q2 September 2018. Consolidated EBITDA margin stood at 21.79% in Q2 FY20 as against 21.37% in Q2 FY19.
Indian formulations income rose 16% to Rs 543.21 crore in Q2 September 2019 over Q2 September 2018. The exports income grew 27% to Rs 588.03 crore in Q2 September 2019 over Q2 September 2018.
The result was announced during market hours today, 7 November 2019.
Ipca Laboratories is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
